Michael Castagna

Michael Castagna is the Chief Executive Officer of MannKind Corporation, a biopharmaceutical company focused on developing and commercializing therapeutic products for patients with diseases such as diabetes. Here are some key details about his background and role:

Professional Experience

Castagna became CEO of MannKind Corporation in May 2017, also joining the company's board of directors at that time.1 Prior to becoming CEO, he served as MannKind's Chief Commercial Officer starting in March 2016.2

He brings over 25 years of experience in the healthcare, pharmaceutical, biotech, and specialty pharmacy industries to his role.25 Before joining MannKind, Castagna held leadership positions at other major pharmaceutical companies:

• Vice President at Amgen, where he led global commercial efforts for biosimilar drugs and lifecycle management2
• Executive Director at Bristol-Myers Squibb, co-leading the relaunch of Orencia for rheumatoid arthritis2

Education and Expertise

Castagna holds a Doctor of Pharmacy (Pharm.D.) degree and later obtained an MBA from a top-tier business school.3 This combination of pharmaceutical expertise and business acumen has shaped his career trajectory in the industry.

Leadership at MannKind

As CEO, Castagna has been instrumental in:

• Leading the commercialization efforts for Afrezza, MannKind's inhaled insulin product12
• Guiding the company's strategic direction and growth
• Expanding MannKind's portfolio, including the acquisition of V-Go, a wearable insulin delivery device4

Castagna's leadership style appears to be driven by a mission to help patients and innovate in the pharmaceutical space, continuing the legacy of MannKind's founder, Alfred Mann.34